Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis

被引:71
作者
Goldberger, Zachary D. [1 ]
Valle, Javier A.
Dandekar, Vineet K.
Chan, Paul S. [2 ]
Ko, Dennis T. [3 ]
Nallamothu, Brahmajee K. [4 ,5 ]
机构
[1] Univ Michigan Hlth Syst, Ctr Cardiovasc, Div Cardiol, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada
[4] Univ Michigan, Sch Med, VA Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA
[5] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA
关键词
DOUBLE-BLIND TRIAL; EXTENDED-RELEASE NIACIN; ARTERIAL-WALL THICKNESS; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; CLINICAL-TRIALS; SUBCLINICAL ATHEROSCLEROSIS; INTRAVASCULAR ULTRASOUND; REDUCING CHOLESTEROL;
D O I
10.1016/j.ahj.2010.06.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Carotid intima-media thickness (CIMT) is increasingly being used as a surrogate end point in randomized control trials (RCTs) of novel cardiovascular therapies. However, it remains unclear whether changes in CIMT that result from these therapies correlate with nonfatal myocardial infarction (MI). Methods We performed a literature search of RCTs from 1990-2009 that used CIMT. Eligible RCTs (1) included quantitative and sequential assessments in CIMT at least 1 year apart and (2) reported nonfatal MI. Across RCTs, random-effects metaregression was employed to correlate differences in mean change in CIMT between treatment and control groups over time with the log odds ratios of developing nonfatal MI during follow-up. Results Overall, we identified 28 RCTs with 15,598 patients. Differences in mean change in CIMT over time between treatment and control groups correlated with developing nonfatal MI during follow-up: for each 0.01 mm per year smaller rate of change in CIMT, the odds ratio for MI was 0.82 (95% CI, 0.69 to 0.96; P = .018). Results were similar in subgroups of RCTs with >1 year follow-up (P = .018) and those with at least 50 subjects in the treatment group (P = .019). However, there was no significant relationship between mean change in CIMT and nonfatal MI in RCTs evaluating statin therapy or those with high CIMTs at baseline (P > .20 in both instances). Conclusions Less progression in CIMT over time is associated with a lower likelihood of nonfatal MI in selected RCTs; however, these findings were inconsistent at times, suggesting caution in using CIMT as a surrogate end point. (Am Heart J 2010; 160: 701-14.)
引用
收藏
页码:701 / 714
页数:14
相关论文
共 60 条
[11]   EFFECT OF PRAVASTATIN ON PROGRESSION AND REGRESSION OF CORONARY ATHEROSCLEROSIS AND VESSEL WALL CHANGES IN CAROTID AND FEMORAL ARTERIES - A REPORT FROM THE REGRESSION GROWTH EVALUATION STATIN STUDY [J].
DEGROOT, E ;
JUKEMA, JW ;
VANBOVEN, AJ ;
REIBER, JHC ;
ZWINDERMAN, AH ;
LIE, KI ;
ACKERSTAFF, RA ;
BRUSCHKE, AVG .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (09) :C40-C46
[12]   Surrogate markers in clinical trials-Challenges and opportunities [J].
Duivenvoorden, Raphael ;
de Groot, Eric ;
Stroes, Erik S. G. ;
Kastelein, John J. P. .
ATHEROSCLEROSIS, 2009, 206 (01) :8-16
[13]   Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors [J].
Espeland, MA ;
O'Leary, DH ;
Terry, JG ;
Morgan, T ;
Evans, G ;
Mudra, H .
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2005, 6 (1)
[14]   Surrogate end points in clinical trials: Are we being misled? [J].
Fleming, TR ;
DeMets, DL .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613
[15]   EFFECT OF LOVASTATIN ON EARLY CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS [J].
FURBERG, CD ;
ADAMS, HP ;
APPLEGATE, WB ;
BYINGTON, RP ;
ESPELAND, MA ;
HARTWELL, T ;
HUNNINGHAKE, DB ;
LEFKOWITZ, DS ;
PROBSTFIELD, J ;
RILEY, WA ;
YOUNG, B .
CIRCULATION, 1994, 90 (04) :1679-1687
[16]   COMPENSATORY ENLARGEMENT OF HUMAN ATHEROSCLEROTIC CORONARY-ARTERIES [J].
GLAGOV, S ;
WEISENBERG, E ;
ZARINS, CK ;
STANKUNAVICIUS, R ;
KOLETTIS, GJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (22) :1371-1375
[17]   Using measures of disease progression to determine therapeutic effect - A sirens' song [J].
Granger, Christopher B. ;
McMurray, John J. V. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (03) :434-437
[18]   Meta-regression in Stata [J].
Harbord, Roger M. ;
Higgins, Julian P. T. .
STATA JOURNAL, 2008, 8 (04) :493-519
[19]   Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study [J].
Hedblad, B. ;
Zambanini, A. ;
Nilsson, P. ;
Janzon, L. ;
Berglund, G. .
JOURNAL OF INTERNAL MEDICINE, 2007, 261 (03) :293-305
[20]   Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness -: Main results from the β-blocker cholesterol-lowering asymptomatic plaque study (BCAPS) [J].
Hedblad, B ;
Wikstrand, J ;
Janzon, L ;
Wedel, H ;
Berglund, G .
CIRCULATION, 2001, 103 (13) :1721-1726